Monday, 16 Sep 2019

You are here

Riociguat Fails in Systemic Sclerosis-Associated Digital Ulcers

Riociguat is an oral, selective soluble guanylate cyclase stimulator that has been studied in patients with digital ulcers (DU) due to systemic sclerosis (SSc) but study results show that short term (16 weeks) riociquat therapy does not sufficiently reduce the DU burden in SSc patients.

SSc patients wwith active or painful indeterminate DUs were enrolled in a -blind, randomized, placebo-controlled, proof-of-concept trial. Patient were treated with placebo or riociguat in individualized doses (maximum of 2.5 mg three times daily) during an 8-week titration period, followed by an 8-week stable dosing period. The primary endpoint was the week 16 change in net ulcer burden (NUB), analyzed using ANCOVA. 

Seventeen participants were enroleld an 8 received placebo and 9 riociguat. Baseline characteristics were comparable between the treatment groups.

At baseline ulcers (NUB) wwere the same in the placebo (2.5) and riociguat (2.4) groups. But there was no significant treatment difference in NUB after 16 weeks of therapy. (adjusted mean treatment difference − 0.24, 95% CI (− 1.46, 0.99), p = 0.70).

Four participants experienced five serious AE (four in riociguat and one in placebo); none was considered related to study medication.

Six participants in each group transitioned to the open-label extension and thos in the riociguat-riociguat arm had complete healing of their DUs.

THese data suggest that long term (not short term) riociguat therapy is necessry to reduce the number of DU net burden in SSc  patients.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Nintedanib FDA Approved for Scleroderma Lung Disease

Last Friday, the US Food and Drug Administration approved Ofev (nintedanib) to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. ILD as a complication of SSc may lead to progressive loss of lung function and may be associated with a significant mortality risk. Prior to the approval of Olev, there were no FDA approved drugs for SSc-ILD.

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS). 

Abatacept Disappoints in Systemic Sclerosis

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)